linjc16/ctgov huggingface dataset:
Sympathetic Overactivity in Essential Hypertension

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is whether subjects with hypertension and proteinuria display increased sympathetic nerve activity compared to hypertensive subjects without proteinuria and normotensive controls.

Official Title
-----------------
Sympathetic Overactivity in Essential Hypertension

Conditions
-----------------
Hypertension, Proteinuria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normotension or hypertension Exclusion Criteria: Pregnant and nursing women Myocardial infarction, clinical signs of coronary heart disease Severe depression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>hypertensives with proteinuria | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, sympathetic activity, early renal damage
Clinical Evaluation for Post Bleaching Hypersensitivity Using Desensitizing Agent During In-office Bleaching

Study Overview
=================
Brief Summary
-----------------
Evaluating the effect of a desensitizing agent on post-bleaching hypersensitivity.

Detailed Description
-----------------
A randomized clinical trail will be done to evaluate the effect of a desensitizing agent ACP oral care gel in comparison to a control group on hypersensitivity after bleaching using a visual analogue scale.

Official Title
-----------------
Clinical Evaluation for Post Bleaching Hypersensitivity Using Desensitizing Agent Before and /or After In-office Bleaching

Conditions
-----------------
Tooth Bleaching

Intervention / Treatment
-----------------
* Other: ACP oral care gel
* Other: glycrin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must show no signs of spontaneous dental pain. Male or female patients between the ages of 18 to 40. Patients with good general and oral health. Patients having six caries-free maxillaryanterior teeth without restorations on the labial surfaces. Patients should have central incisors determined to be shade C2 or darker Exclusion Criteria: Patient with spontaneous dental pain. Patient with anterior restorations or non carious cervical lesion. Patient having severe internal tooth discoloration (tetracycline stains, fluorosis, pulpless teeth), and bruxism habits. Tempro-mandibular joint problems involving symptomatic pain. Patients taking analgesics that could alter their normal pain perception level. Pregnant or breast feeding women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ACP oral care geldesensitizing agent<br>a desensitizing agent will be applied on tooth before and /or after bleaching. | Other: ACP oral care gel<br>* a desensitizing agent will be applied on tooth before and/or after bleaching<br>|
| Placebo Comparator: glycrin<br>glycrin will be applied on tooth before and /or after bleaching. | Other: glycrin<br>* glycrin will be applied on tooth surface before and/or after bleaching<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-bleaching hypersensitivity assessed using visual analogue scale | using visual analogue scale | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tooth color assessed using value-ordered VITA® Classical Shade Guide | value-ordered VITA® Classical Shade Guide | one month |
High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the effect of high dose and low dose of Atorvastatin in reduction level of C-reactive protein (CRP) in patients with unstable angina and NSTEMI (Non ST Elevation MI) attending Shahid Mohammadi hospital in Bandar Abbas.

Detailed Description
-----------------
This study compare the effect of 80mg atorvastatin followed by two 20mg daily atorvastatin with three 80mg daily atorvastatin in reduction of CRP in patients with unstable angina and NSTEMI (Non ST Elevation MI) attending Shahid Mohammadi hospital in Bandar Abbas in 2009.

Official Title
-----------------
Comparison Between Effect of High Dose and Low Dose of Atorvastatin in Reduction Level of CRP in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)

Conditions
-----------------
Cardiovascular Disease

Intervention / Treatment
-----------------
* Drug: Low dose Atorvastatin
* Drug: High dose atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with unstable angina with chest discomfort at rest with normal EKG or St depression (at least 0.1mv) in two consecutive leads or new and deep T inversion (at least 0.2mv) Exclusion Criteria: Myocardial Infarction with ST elevation Diabetes Mellitus Previous statin use Current infectious disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: High dose atorvastatin<br>Three 80mg daily doses of atorvastatin | Drug: Low dose Atorvastatin<br>* 80mg atorvastatin followed by two 20mg daily atorvastatin<br>* Other names: Lipitor;|
| Experimental: Low dose Atorvastatin<br>80mg atorvastatin followed by two 20mg daily atorvastatin | Drug: High dose atorvastatin<br>* 80mg daily atorvastatin for 72 hours<br>* Other names: Lipitor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CRP reduction | CRP reduction will be compared between two study groups | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug side effects | Headache, Myopathy | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Unstable angina, NSTMI, Statin, Atorvastatin
Degradation of the Anorexic Hormone Peptide YY

Study Overview
=================
Brief Summary
-----------------
Peptide YY (PYY) is a gastrointestinal hormone released from the enteroendocrine cell upon food intake. The N-terminal truncated form, PYY3-36, exerts anorexic effects. In this study we want to investigate the kinetics of PYY1-36 and PYY3-36 and to examine whether a C-terminally degraded metabolite, PYY3-34, is formed after infusion of PYY.

Official Title
-----------------
Degradation of the Anorexic Hormone Peptide YY

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Biological: PYY1-36 infusion
* Biological: PYY1-36 + sitagliptin
* Biological: PYY3-36 infusion
* Biological: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Normal BMI (18.5-25kg/m2) Exclusion Criteria: Diabetes Mellitus Gastric bypass Non-caucasian Height changes >3 kg within last two months Hemoglobin < 7.6 mmol/l Chronic disease Smoking Regularly use of medicine Drug abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PYY infusion<br>IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years | Biological: PYY1-36 infusion<br>* Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.<br>Biological: PYY1-36 + sitagliptin<br>* Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.<br>Biological: PYY3-36 infusion<br>* 0.8 pmol/kg/min infusion of PYY3-36.<br>Biological: placebo<br>* Infusion of saline for 2 hrs.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PYY3-34 concentration |  | 0-240 min | 
| Half-lives of PYY1-36 and PYY3-36 |  | 0-240 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PYY, Degradation, kinetics, men
Patient Initiated Note About Goals

Study Overview
=================
Brief Summary
-----------------
This is a randomized controlled trial of the Patient-Initiated Note about Goals (PING).

Detailed Description
-----------------
The PING is a brief survey designed to elicit patients' goals, preferences, and preferred surrogate decision-maker. In the PING study, patients will be assigned to receive either a nurse-administered PING or usual care. Outcomes include PING completion, subsequent goals of care conversations with providers, and healthcare utilization.

Official Title
-----------------
Patient Initiated Note About Goals

Conditions
-----------------
Chronic Disease

Intervention / Treatment
-----------------
* Behavioral: PING


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient referred for Annual Wellness Visit at participating clinic Exclusion Criteria: Non-English speaking

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Parallel RCT
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Patients receive PING administered by RN | Behavioral: PING<br>* Brief survey of goals and preferences<br>|
| No Intervention: Control<br>Usual care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with subsequent goals of care conversation | Conversation documented in EHR (electronic health record) | 2 months |
Spinal Arthrodesis and Spinal Arthroplasty Database Study

Study Overview
=================
Brief Summary
-----------------
To collect and organize data into a repository for future research.

Detailed Description
-----------------
To collect and organize data into a repository from the Principal Investigator's (H. Francis Farhadi, MD, PhD) patients who are undergoing spinal arthrodesis and/or spinal arthroplasty procedures at Ohio State University for future research, as yet to be identified. This comprehensive database of patients will allow for gathering of relevant information for potential future research use.

Official Title
-----------------
General Spinal Arthrodesis and Spinal Arthroplasty Database

Conditions
-----------------
Spine Condition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have had or will undergo a spinal arthrodesis and/or spinal arthroplasty procedure at Ohio State University Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| spinal arthrodesis and/or arthroplasty procedures<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical prospective review- Prospective Database study for future studies | Collecting clinical measurements. Examples of these clinical measurements are the VAS Pain Scale, SF-36, NDI, and ODI. | 5 years |
SPIROCOR Coronary Outcome by Respiratory Stress Examination

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to validate the accuracy of the SPIROCOR System in indicating the presence of significant coronary artery disease (S-CAD), as defined in ACC/AHA Guidelines, in subjects with suspected S-CAD.

Official Title
-----------------
SPIROCOR Coronary Outcome by Respiratory Stress Examination - SCORE Study

Conditions
-----------------
Severe Coronary Artery Disease (S-CAD)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject with suspected S-CAD Subject able to perform the guided breathing protocol and comply with study requirements Subject is able and agrees to sign the informed consent form Exclusion Criteria: Resting (supine) ECG evidence of ST-segment depression ≥ 1 mm in any lead or left bundle branch block or significant arrhythmia Current digoxin therapy Subject has severe valvular heart disease Subject has congestive heart failure NYHA class III/IV Subject has known history of myocardial infarction (ST elevation or non ST elevation) Subject had previous coronary revascularization: CABG or PCI Subject has pacemaker or ICD that controls sinus Morbidly obese subject (BMI ≥ 40) Subject has any significant medical condition which, at the investigator's discretion, may interfere with the subject's optimal participation in the study; and Subject is currently participating in another investigational product clinical study that the investigator believes may interfere with the outcome of this study

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RSR vs. S-ECG in subjects suspected with S-CAD |  | 3 weeks window | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RSR, SECG, SPECT, QCA, SCAD
Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
Preclinical studies at our institution, based on a genetic mouse model of stomach cancer, strongly suggest that innervation of the stomach wall is deeply involved in tumorigenesis of stomach cancer. The data indicate that denervation of the stomach either by vagotomy or by injection of botulinum toxin (Botox®)in the stomach wall inhibits the development of cancer as well as reduces already established tumor volume in the stomach in this mouse model. Gene expression data indicate that vagotomy suppresses protein gene product 9.5 (PGP9.5). The expression of PGP9.5 is highly specific for the density of neurons and the diffuse neuroendocrine system. The investigators will take biopsies from tumors and adjacent normal mucosa either by means of endoscopy and/or from operative specimens from participants treated or evaluated for stomach cancer at the Department of Gastrointestinal Surgery, St Olavs Hospital, Trondheim University Hospital. The biopsies will be evaluated with immunohistochemistry and gene expression studies for the presence and density of PGP9.5. These data will be correlated to stage evaluation (TNM) and survival.

Official Title
-----------------
Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma

Conditions
-----------------
Stomach Neoplasms

Intervention / Treatment
-----------------
* Procedure: biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fifteen patients evaluated- or treated for suspected or verified gastric adenocarcinoma at the Department of Gastrointestinal Surgery, St Olavs Hospital, Trondheim University Hospital informed consent Exclusion Criteria: General contraindications for endoscopy with biopsies (i.e. bleeding disorders or use of anticoagulants).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: biopsy<br>Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient. | Procedure: biopsy<br>* biopsies will be evaluated with immunohistochemistry and gene expression studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Density of PGP9.5 in gastric adenocarcinoma related to TNM stage and survival of stomach cancer |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tumor Markers, Biological, PGP9.5 protein, human, adenocarcinoma
RapidShock Post-Approval Study

Study Overview
=================
Brief Summary
-----------------
Compare the performance of the Reconfirmation Analysis Mode algorithm to the performance goals recommended by the American Heart Association.

Official Title
-----------------
Post-Approval Study for Reconfirmation Analysis Mode Algorithm

Conditions
-----------------
Cardiac Arrest

Intervention / Treatment
-----------------
* Device: RapidShock


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 8 years of age or older and weight ≥ 55 lbs (25 kgs) Out-of-hospital cardiac arrest (OOHCA) Non-traumatic cardiac arrest Exclusion Criteria: Weight less than 55 lbs (25 kgs) Do not attempt resuscitation (DNAR) orders

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: RapidShock<br>Patients receiving xseries device with rapid shock enabled | Device: RapidShock<br>* Use of the Reconfirmation Analysis Mode algorithm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Algorithm accuracy | Accuracy of the algorithm compared to manual annotation for each rhythm | average of up to 1 hour after device placement |
Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to provide individuals that have a balance deficit with a device that will give them signals that they can feel (vibrations) in order to help them maintain a correct sense of balance and perception of place in the environment.

Detailed Description
-----------------
This proposal addresses a National Institute on Deafness and Other communication Disorders (NIDCD) research topic that emphasizes the development of assistive devices for balance disorders. The proposed work will evaluate the assistive efficacy of such a balance prosthesis in a population of chronic imbalance patients spanning a wide range of disease etiologies.

Official Title
-----------------
Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability

Conditions
-----------------
Dizziness

Intervention / Treatment
-----------------
* Device: balance prosthesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ambulatory patients who have had chronic imbalance for at least one year, and have reached a functional performance plateau with respect to their balance adaptation. Exclusion Criteria: Neurological disorders other than chronic balance disorders, as determined by medical history and neurological screening procedure. Any medical condition as determined by the health questionnaire that would interfere with performance on the postural stability evaluation tests. Peripheral neuropathies of the lower extremities. Subjects who are unwilling or unable to adhere to all study requirements, including completion of the training period, evaluation tests, and return to clinic for a follow-up visit.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: prosthesis group<br>balance prosthesis | Device: balance prosthesis<br>* vibrotactile stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Dynamic Gait Index (DGI) From Baseline to 6 Weeks. | The DGI is designed to measure a patient's functional balance and postural stability on a scale of 0-3 (3 being normal) for each task. A series of 8 tasks including walking on a level surface, walking while changing speeds, walking with head turns, walking then turning, stepping over obstacles, walking around obstacles, and stairs. For a total scale of 0-24. | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic imbalance, vestibular disorders, balance prosthesis